Doctors urged to review patients on phenelzine amid shortage
Patients will need special care to taper off and switch to alternatives, says president of psychiatrists' college
Patients taking phenelzine to treat major depression disorder will need to be reviewed after the sponsor of the drug discontinued its supply, a leading psychiatrist says.
Australian-based pharmaceutical company Link Medical Products notified the TGA in April that it was no longer producing Nardil (phenelzine sulfate) 15mg tablets due to manufacturing issues.
In response to a nationwide shortage, the TGA had approved the supply of an alternative, overseas-registered product but has since been advised that these tablets are also not currently